TY - JOUR T1 - Evaluating the Prevalence of Plasminogen Activator Inhibitor-1 Gene Polymorphism in Patients with Thyroid Tumors from North West of Iran TT - بررسی شیوع پلی مورفیسم ژن مهار کننده فعال کننده پلاسمینوژن-1 در بیماران مبتلا به تومور های تیروئیدی از شمال غرب ایران JF - sjimu JO - sjimu VL - 25 IS - 2 UR - http://sjimu.medilam.ac.ir/article-1-3252-en.html Y1 - 2017 SP - 166 EP - 172 KW - Polymorphism KW - Plasminogen activation system KW - Thyroid tumors N2 - Introduction: Association of PAI-1 polymorphisms with the increased risk of various malignancies has been shown in numerous studies. Therefore, the aim of the current study is to evaluate the prevalence of PAI-1 4G/5G polymorphism in patients with thyroid tumors from North West of Iran. Materials & methods: Ninety patients with thyroid tumors and 180 healthy controls were selected from North West of Iran. DNA was extracted from peripheral blood samples and 4G/5G polymorphism of the PAI-1 gene was evaluated by polymerase chain reaction using specific primers. Findings: Genotype distribution between patients was (4G/4G=13.33%, 4G/5G=63.33% and 5G/5G=23.33%) and controls (4G/4G=17.22%, 4G/5G=67.22% and 5G/5G=15.55%). Additionally, the frequencies of the 4G and 5G alleles between patients were (45% and 55%) and control group (50.83% and 49.16%). Discussion & conclusions: Results indicate that the genotypic and allelic frequencies of PAI-1 4G/5G polymorphism showed no significant difference between patients with thyroid tumors and control individuals in this cohort. M3 10.29252/sjimu.25.2.166 ER -